These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22362332)

  • 1. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis.
    Madeddu R; Farace C; Tolu P; Solinas G; Asara Y; Sotgiu MA; Delogu LG; Prados JC; Sotgiu S; Montella A
    Neurol Sci; 2013 Feb; 34(2):181-6. PubMed ID: 22362332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
    Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
    Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
    Norgren N; Sundström P; Svenningsson A; Rosengren L; Stigbrand T; Gunnarsson M
    Neurology; 2004 Nov; 63(9):1586-90. PubMed ID: 15534240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.
    Malmeström C; Haghighi S; Rosengren L; Andersen O; Lycke J
    Neurology; 2003 Dec; 61(12):1720-5. PubMed ID: 14694036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability.
    Semra YK; Seidi OA; Sharief MK
    J Neuroimmunol; 2002 Jan; 122(1-2):132-9. PubMed ID: 11777552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
    Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
    Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing tissue damage in multiple sclerosis: a biomarker approach.
    Burman J; Zetterberg H; Fransson M; Loskog AS; Raininko R; Fagius J
    Acta Neurol Scand; 2014 Aug; 130(2):81-9. PubMed ID: 24571714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS.
    Novakova L; Singh AK; Axelsson M; Ståhlman M; Adiels M; Malmeström C; Zetterberg H; Borén J; Lycke J; Cardell SL; Blomqvist M
    J Neurochem; 2018 Aug; 146(3):322-332. PubMed ID: 29676479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid markers in MS patients and their healthy siblings.
    Haghighi S; Andersen O; Odén A; Rosengren L
    Acta Neurol Scand; 2004 Feb; 109(2):97-9. PubMed ID: 14705970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can CSF biomarkers predict future MS disease activity and severity?
    Magliozzi R; Cross AH
    Mult Scler; 2020 Apr; 26(5):582-590. PubMed ID: 31965889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.
    Tortosa-Carreres J; Cubas-Núñez L; Quiroga-Varela A; Castillo-Villalba J; Ramió-Torrenta L; Piqueras M; Gasqué-Rubio R; Quintanilla-Bordas C; Sanz MT; Lucas C; Huertas-Pons JM; Miguela A; Casanova B; Laiz-Marro B; Pérez-Miralles FC
    Mult Scler Relat Disord; 2024 Aug; 88():105734. PubMed ID: 38909525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light chain in the assessment of patients with multiple sclerosis.
    Domingues RB; Fernandes GBP; Leite FBVM; Senne C
    Arq Neuropsiquiatr; 2019 Jul; 77(6):436-441. PubMed ID: 31314847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.